目的:探讨双歧杆菌四联活菌片联合莫沙必利治疗老年功能性便秘的临床疗效、安全性,及对患者肠道功能的改善作用。方法:功能性便秘老年患者128例随机分为观察组和对照组,每组64例,对照组患者应用莫沙必利片治疗,观察组患者给予双歧杆菌四联活菌片联合莫沙必利片治疗。疗程4周。评估两组患者临床疗效、主要症状或体征的改善状况及药品不良反应。结果:观察组显效率为78.13%,高于对照组60.94%(P<0.05)。观察组患者症状改善时间低于对照组(P<0.05),治疗后排便困难、粪便性状、排便不尽感和排便间隔评分均低于对照组(P<0.05);两组患者药品不良反应发生率比较,差异无统计学意义(P>0.05)。结论:双歧杆菌四联活菌片联合莫沙必利治疗老年功能性便秘的临床疗效较好,能明显改善患者的临床症状或体征,缩短患者好转时间,并具有较好的安全性。 Objective: To investigate the clinical efficacy and safety of bifidobacterium quadricepsilz combined with mosapride in the treatment of elderly patients with functional constipation and its effect on improving intestinal function in patients. Methods: 128 cases of elderly patients with functional constipation were randomly divided into observation group and control group, 64 cases in each group. Patients in the control group were treated with mosapride, and patients in observation group were given live bifidobacterium Lee tablets treatment. Treatment for 4 weeks. The clinical efficacy, improvement of the main symptoms or signs and adverse drug reactions in both groups were evaluated. Results: The effective rate of observation group was 78.13%, higher than that of control group 60.94% (P <0.05). The symptom improvement time in the observation group was lower than that in the control group (P <0.05). After treatment, the defecation difficulty, stool performance, defecation feeling and defecation interval score were lower than those in the control group (P <0.05). Adverse reactions occurred in both groups There was no significant difference in rates (P> 0.05). Conclusion: The combination of Bifidobacterium quadricepsil and mosapride in the treatment of senile functional constipation has better curative effect, can significantly improve the clinical symptoms or signs of patients, shorten the time of patients’ improvement, and has good safety.